HATFIELD, England, December 1, 2014 /PRNewswire/ --
FOR EMEA MEDIA ONLY: NOT FOR SWISS/U.S. JOURNALISTS
Eisai presents new and important data for women with breast cancer
Five abstracts to be presented at 2014 San Antonio Breast Cancer Symposium (SABCS), highlight new data for Halaven® (eribulin). The meeting will be held 9-13 December 2014 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
These studies highlight Eisai's ongoing clinical research efforts with eribulin, reinforcing the company's commitment to continued research for patients and their families affected by metastatic breast cancer (MBC).
"Eisai remains committed to evaluating further the safety and efficacy of eribulin in women living with locally advanced or MBC. The data presented at this year's SABCS demonstrate our commitment to discovering, developing and producing innovative oncology therapies that can make a difference and impact positively the lives of patients and their families," commented Gary Hendler, President & CEO Eisai EMEA and President, Eisai Oncology Global Business Unit.
The following Eisai abstracts are accepted for presentation at this year's San Antonio Breast Cancer Symposium:
Product Abstract Name Abstract No: Efficacy of eribulin in patients with invasive lobular P3-13-04 carcinoma of the breast: data from a pooled analysis Poster Session: Cortes J, Perez J, Metzger O, He P P3-13 Abstract No: Efficacy and safety of eribulin in combination with P3-13-06 capecitabine in patients with metastatic breast cancer: Poster Session: an open-label, phase 2 dose-confirmation study P3-13 Evans J, Twelves C, Anthoney A, Savulsky C, Nasim M, Shuxin Y Abstract No: Quality of life results from a phase 2, multicenter, P5-17-03 single-arm study of eribulin mesylate plus trastuzumab Poster Session: as first-line therapy for locally recurrent or P5-17 metastatic HER2+ breast cancer Schwartzberg L, Wilks S, Puhalla S, O'Shaughnessy J, Berrak E, Song J, Cox D, Vahdat L Abstract No: Quality of life in patients receiving first-line P5-17-02 eribulin mesylate for HER2- locally recurrent or MBC Poster Session: Schwartzberg L, McIntyre K, O'Shaughnessy J, Gluck S, P5-17 Berrak E, Song J, Cox D, Vahdat L Abstract No: Eribulin mesylate plus capecitabine for adjuvant P3-09-09 treatment in post-menopausal ER+ early-stage breast Poster Session: cancer: a phase 2, multicenter, open-label study using P3-09 2 different dosage regimens Smith II JW, Vukelja S, Hoffman A, Jones V, McIntyre K, Berrak E, Teng A, Cox D, O'Shaughnessy J
The information discussed in this release is about investigational uses for eribulin. In Europe, eribulin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments. It is not intended to convey conclusions of efficacy and safety.
Notes to Editors
Eribulin is the first in the halichondrin class of microtubule dynamics inhibitors with a novel mechanism of action. Structurally eribulin is a simplified and synthetically produced version of halichondrin B, a natural product isolated from the marine sponge Halichondria okadai. Eribulin is believed to work by inhibiting the growth phase of microtubule dynamics which prevents cell division.
Eribulin is currently indicated for the treatment of women with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting, unless patients were not suitable for these treatments.
Metastatic Breast Cancer
Over 300,000 women are diagnosed with breast cancer in Europe every year, of whom about one third subsequently develop metastatic disease.,Metastatic disease is an advanced stage of the disease that occurs when cancer spreads beyond the breast to other parts of the body.
Eisai in Oncology
Our commitment to meaningful progress in oncology research, built on scientific expertise, is supported by a global capability to conduct discovery and preclinical research, and develop small molecules, therapeutic vaccines, and biologic and supportive care agents for cancer across multiple indications.
About Eisai Co., Ltd.
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realise our hhc philosophy by delivering innovative products in multiple therapeutic areas with high unmet medical needs, including Oncology and Neurology.
As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.
For more information about Eisai Co., Ltd., please visit http://www.eisai.com.
1. Halaven, Summary of Product Characteristics (updated July 2014): http://www.medicines.org.uk/emc/medicine/24382
2. World Health Organisation. Atlas of Health in Europe. 2003. World Health Organization, Regional Office of Europe, Copenhagen, Denmark.
3. Cancer Research UK. Breast cancer incidence statistics. Available at: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/incidence/#world . Accessed: October 2014.
Date of preparation: November 2014
Job code: Halaven-UK0370
SOURCE Eisai Europe Limited